Results 21 to 30 of about 173,364 (256)

Pulmonary arterial hypertension [PDF]

Orphanet Journal of Rare Diseases, 2013
Abstract Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimately death if untreated. The first classification of PH was proposed in 1973. In 2008, the fourth World Symposium on PH held in Dana Point (California, USA) revised previous classifications.
Montani, David, Günther, Sven, Dorfmüller, Peter, Perros, Frédéric, Girerd, Barbara, Garcia, Gilles, Jaïs, Xavier, Savale, Laurent, Artaud-Macari, Elise, Price, Laura, Humbert, Marc, Simonneau, Gérald, Sitbon, Olivier   +12 more
openaire   +3 more sources

Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension

Pulmonary Circulation, 2020
Platelet-derived growth factor is one of the major growth factors found in human and mammalian serum and tissues. Abnormal activation of platelet-derived growth factor signaling pathway through platelet-derived growth factor receptors may contribute to ...
Kang Wu, Haiyang Tang, Ruizhu Lin, Shane G. Carr, Ziyi Wang, Aleksandra Babicheva, Ramon J. Ayon, Pritesh P. Jain, Mingmei Xiong, Marisela Rodriguez, Shamin Rahimi, Francesca Balistrieri, Shayan Rahimi, Daniela Valdez-Jasso, Tatum S. Simonson, Ankit A. Desai, Joe G.N. Garcia, John Y.-J. Shyy, Patricia A. Thistlethwaite, Jian Wang, Ayako Makino, Jason X.-J. Yuan   +21 more
doaj   +1 more source

Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers

Pulmonary Circulation, 2021
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros, Samara M.A. Jansen, Ali Ashek, Onno A. Spruijt, Jelco Tramper, Anton Vonk Noordegraaf, Jurjan Aman, Hans Harms, Frances S. deMan, Marc C. Huisman, Lan Zhao, Harm J. Bogaard   +11 more
doaj   +1 more source

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
John J. Ryan, Lana Melendres-Groves, Roham T. Zamanian, Ronald J. Oudiz, Murali Chakinala, Erika B. Rosenzweig, Mardi Gomberg-Maitland   +6 more
doaj   +1 more source

Pulmonary artery denervation for pulmonary arterial hypertension

Trends in Cardiovascular Medicine, 2021
Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation.
Constantine, A, Dimopoulos, K
openaire   +3 more sources

High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude

Pulmonary Circulation, 2020
While estimates of pulmonary arterial hypertension incidence and prevalence commonly range from 1–3/million and 15–25/million, respectively, clinical experience at our institution suggested much higher rates.
Jason Dubroff, Lana Melendres, Yan Lin, Daniel Raley Beene, Loren Ketai   +4 more
doaj   +1 more source

Clinical implications of partial anomalous pulmonary venous connection: a rare cause of severe pulmonary arterial hypertension

Pulmonary Circulation, 2020
Isolated partial anomalous pulmonary venous connection (PAPVC) is an uncommon congenital heart anomaly that is sporadically associated with pulmonary arterial hypertension in the adult population.
Alex Pizzini, Thomas Sonnweber, Renate Frank, Markus Theurl, Günter Weiss, Ivan Tancevski, Judith Löffler-Ragg   +6 more
doaj   +1 more source

Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension

Journal of Cardiothoracic Surgery, 2021
Pulmonary arterial hypertension is a type of malignant pulmonary vascular disease, which is mainly caused by the increase of pulmonary vascular resistance due to the pathological changes of the pulmonary arteriole itself, which eventually leads to right ...
Jianying Deng
doaj   +1 more source

Incident pulmonary arterial hypertension associated with Bosutinib

Pulmonary Circulation, 2020
Pulmonary arterial hypertension is associated with tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia. Dasatinib is a known cause of drug-induced pulmonary arterial hypertension.
Shaun Yo, John Thenganatt, Jeffrey Lipton, John Granton   +3 more
doaj   +1 more source

Genetics of Pulmonary Arterial Hypertension [PDF]

Seminars in Respiratory and Critical Care Medicine, 2009
Tremendous progress has been made in understanding the genetics of pulmonary arterial hypertension (PAH) since its description in the 1950s as a primary disorder of the pulmonary vasculature. Heterozygous germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable PAH, and in ...
Eric D, Austin, James E, Loyd, John A, Phillips   +2 more
openaire   +3 more sources